Top
 

Core Diagnostics

Nview Health / Core Diagnostics

Our behavioral health solutions are used by mental health professionals and healthcare organizations in over 100 countries.

The M.I.N.I. Diagnostic Interview

Nview’s core diagnostic instrument — the Mini International Neuropsychiatric Interview (M.I.N.I.) — has been used in patient care and clinical research for more than 25 years.

The M.I.N.I. is a short, structured diagnostic interview designed to evaluate the most common DSM-5 and ICD-10 psychiatric disorders. With an administration time of approximately 15 minutes, the M.I.N.I. is the structured psychiatric interview of choice for psychiatric evaluation and outcome tracking in clinical psychopharmacology trials and epidemiological studies.

The M.I.N.I. is the most widely used psychiatric structured diagnostic interview instrument in the world, employed by mental health professionals and health organizations in more than 100 countries.

The M.I.N.I was originally created by one of Nview’s Co-Founders and Chief Scientific Officer, David V. Sheehan, M.D., M.B.A., DLFAPA, and by Yves Lecrubier, M.D., associated with the Centre Hospitalier Sainte-Anne in Paris, France. Dr. Sheehan is Distinguished University Health Professor Emeritus at the University of South Florida College of Medicine.

The M.I.N.I. has been validated against the longer Structured Clinical Interview for DSM diagnoses (SCID-P) in English and in French and against the longer Composite International Diagnostic Interview for ICD-10 (CIDI) in English, French and Arabic.

The Sheehan Scales

Nview’s outcome tracking solutions include the Sheehan Disability Scale (SDS), that provides a simple, short assessment of functional impairment or disability at work, in social settings and with family; and the Sheehan Suicidality Scale (S-STS) that assesses suicidal thoughts, impulses and behaviors.

Sheehan Disability Scale

The Sheehan Disability Scale is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient’s life are impaired by symptoms. This scale has been used in randomized controlled trials in psychiatry and medicine, and in health economic research. This anchored discretized visual analog scale uses visual-spatial, numeric, and verbal descriptive anchors simultaneously to assess disability across three domains: work, social life, and family life.

Sheehan Suicidality Tracking Scale

The Sheehan Suicidality Tracking Scale (S-STS) assesses the seriousness of suicidal thoughts, plans, intent, impulses, hallucinations, preparatory behaviors and suicide attempts. The Sheehan Suicidality Tracking Scale can be used as a patient self-report or as a clinician-administered rating scale that tracks treatment-emergent suicidal ideation and behaviors. It may also be a psychometric instrument designed to be sensitive to change and to discriminate drug from placebo in randomized trials.

The Sheehan Suicidality Tracking Scale maps to the FDA endorsed Columbia Classification Algorithm of Suicide Assessment (C-CASA) and to the suicidality categories in the 2012 FDA Draft Guidance Document for the Assessment of Suicidal Ideations and Behaviors. This 2012 Draft Guidance document serves as a guidance to industry for retrospective classification of suicidal events in clinical trials.

2016
THE COMPLETE AND
OFFICAL CODEBOOK
ICD
10-CM

AMERICAN MEDICAL
ASSOCIATION

DIAGNOSTIC AND
STATISTICAL MANUAL
OF MENTAL DISORDERS
DSM-V
AMERICAN PSYCHIATRIC
ASSOCIATION